TALKSPACE INC (TALK)

US87427V1035 - Common Stock

3.12  +0.04 (+1.3%)

After market: 3.12 0 (0%)

Fundamental Rating

4

Taking everything into account, TALK scores 4 out of 10 in our fundamental rating. TALK was compared to 117 industry peers in the Health Care Providers & Services industry. TALK has a great financial health rating, but its profitability evaluates not so good. TALK shows excellent growth, but is valued quite expensive already.



1

1. Profitability

1.1 Basic Checks

In the past year TALK has reported negative net income.
In the past year TALK has reported a negative cash flow from operations.
In the past 5 years TALK always reported negative net income.
TALK had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -13.48%, TALK is doing worse than 70.69% of the companies in the same industry.
TALK's Return On Equity of -16.16% is in line compared to the rest of the industry. TALK outperforms 43.97% of its industry peers.
Industry RankSector Rank
ROA -13.48%
ROE -16.16%
ROIC N/A
ROA(3y)-30.84%
ROA(5y)-46.01%
ROE(3y)-37.09%
ROE(5y)-76.75%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

TALK has a better Gross Margin (49.57%) than 79.31% of its industry peers.
In the last couple of years the Gross Margin of TALK has declined.
TALK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.8%
GM growth 5YN/A

8

2. Health

2.1 Basic Checks

TALK does not have a ROIC to compare to the WACC, probably because it is not profitable.
TALK has more shares outstanding than it did 1 year ago.
There is no outstanding debt for TALK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 12.09 indicates that TALK is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 12.09, TALK belongs to the top of the industry, outperforming 97.41% of the companies in the same industry.
TALK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.09
ROIC/WACCN/A
WACC9.34%

2.3 Liquidity

TALK has a Current Ratio of 6.46. This indicates that TALK is financially healthy and has no problem in meeting its short term obligations.
TALK has a Current ratio of 6.46. This is amongst the best in the industry. TALK outperforms 96.55% of its industry peers.
A Quick Ratio of 6.46 indicates that TALK has no problem at all paying its short term obligations.
TALK's Quick ratio of 6.46 is amongst the best of the industry. TALK outperforms 97.41% of its industry peers.
Industry RankSector Rank
Current Ratio 6.46
Quick Ratio 6.46

7

3. Growth

3.1 Past

TALK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.00%, which is quite impressive.
TALK shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.51%.
Measured over the past years, TALK shows a very strong growth in Revenue. The Revenue has been growing by 25.34% on average per year.
EPS 1Y (TTM)76%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q90.91%
Revenue 1Y (TTM)25.51%
Revenue growth 3Y25.34%
Revenue growth 5YN/A
Revenue growth Q2Q40.27%

3.2 Future

TALK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.79% yearly.
TALK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.63% yearly.
EPS Next Y105.67%
EPS Next 2Y56.63%
EPS Next 3Y45.22%
EPS Next 5Y24.79%
Revenue Next Year30.96%
Revenue Next 2Y24.67%
Revenue Next 3Y22.72%
Revenue Next 5Y23.63%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

1

4. Valuation

4.1 Price/Earnings Ratio

TALK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 458.59, TALK can be considered very expensive at the moment.
TALK's Price/Forward Earnings is on the same level as the industry average.
TALK is valuated expensively when we compare the Price/Forward Earnings ratio to 21.49, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 458.59

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
TALK's earnings are expected to grow with 45.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y56.63%
EPS Next 3Y45.22%

0

5. Dividend

5.1 Amount

No dividends for TALK!.
Industry RankSector Rank
Dividend Yield N/A

TALKSPACE INC

NASDAQ:TALK (4/26/2024, 4:47:43 PM)

After market: 3.12 0 (0%)

3.12

+0.04 (+1.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap526.97M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 458.59
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.48%
ROE -16.16%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 49.57%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 6.46
Quick Ratio 6.46
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)76%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y105.67%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)25.51%
Revenue growth 3Y25.34%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y